Woodline Partners LP Has $15.33 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Woodline Partners LP boosted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 124.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 423,828 shares of the specialty pharmaceutical company's stock after purchasing an additional 235,257 shares during the period. Woodline Partners LP owned about 0.77% of Supernus Pharmaceuticals worth $15,326,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in SUPN. Vident Advisory LLC raised its stake in shares of Supernus Pharmaceuticals by 2.2% in the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock worth $520,000 after acquiring an additional 309 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Supernus Pharmaceuticals by 7.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company's stock worth $190,000 after acquiring an additional 369 shares during the last quarter. Bank of Montreal Can raised its stake in shares of Supernus Pharmaceuticals by 6.6% in the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after acquiring an additional 473 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in shares of Supernus Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company's stock worth $800,000 after acquiring an additional 560 shares during the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Supernus Pharmaceuticals by 7.3% in the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock worth $330,000 after acquiring an additional 624 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, May 16th.

Supernus Pharmaceuticals Stock Performance

SUPN traded up $0.06 during midday trading on Friday, reaching $32.10. 330,988 shares of the company were exchanged, compared to its average volume of 483,726. The stock has a market capitalization of $1.80 billion, a P/E ratio of 30.00 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28. The stock's 50-day simple moving average is $31.98 and its 200 day simple moving average is $34.75.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.